Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes
Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes
复制标题
DOI：
10.1039/b508531b
复制
发表时间：
2005-01-01
影响因子：
4.9
通讯作者：
Sadler, PJ
中科院分区：
文献类型：
--
作者：
Yan, YK;Melchart, M;Sadler, PJ
我们的工作表明，某些钌（II）芳烃配合物在体外和体内表现出有前途的抗癌活性。复合物是稳定的和水溶性的，并且它们的框架提供了相当大的范围来优化设计，无论是在它们的生物活性方面，还是通过芳烃和其他配位配体的变化来最小化副作用。对氨基酸和核苷酸的初步研究表明，可以实现对Ru（II）芳烃配合物与生物分子的广谱反应的动力学和热力学控制。这些钌（II）芳烃配合物似乎有一个改变的生物活性与金属为基础的抗癌配合物相比，目前在临床使用或临床试验。
Our work has shown that certain ruthenium(II) arene complexes exhibit promising anticancer activity in vitro and in vivo. The complexes are stable and water-soluble, and their frameworks provide considerable scope for optimising the design, both in terms of their biological activity and for minimising side-effects by variations in the arene and the other coordinated ligands. Initial studies on amino acids and nucleotides suggest that kinetic and thermodynamic control over a wide spectrum of reactions of Ru(II) arene complexes with biomolecules can be achieved. These Ru( II) arene complexes appear to have an altered profile of biological activity in comparison with metal-based anticancer complexes currently in clinical use or on clinical trial.